Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:35 AM ET 8-K
M&A Deal Silgan Holdings Inc SLGN

Silgan Holdings Signs $3.4B M&A Deal with Trivium Packaging B.V.

Silgan Holdings announced a transformational deal to combine its Metal Containers and flat cap closures businesses with Trivium Packaging B.V. to create a new $7.3 billion partnership called Silgan Metal Containers and Closures (Silgan MCC). Silgan will retain a 60% controlling interest in the partnership while receiving $2.3 billion in cash proceeds, with the acquisition of Trivium valued at an enterprise value of approximately $3.4 billion.

Value
$3.4B
Counterparty
Trivium Packaging B.V.

“This strategic portfolio acceleration reflects our commitment to value creation through deliberate portfolio construction and strategic capital deployment, enabled by the strength of our businesses and our exceptional teams.”

Adam Greenlee, President and Chief Executive Officer
7:13 AM ET 8-K
Contract Win Marker Therapeutics, Inc. MRKR

Marker Therapeutics Wins $2.6M Contract from Food & Drug Administration

Marker Therapeutics was awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to advance its lead MAR-T cell therapy, MT-601, for pancreatic cancer. The non-dilutive funding will support a Phase 1 clinical study in patients with locally advanced unresectable pancreatic cancer. Marker was one of only six recipients selected from 66 applications in fiscal year 2026.

Value
$2.6M
Counterparty
Food & Drug Administration
7:08 AM ET 8-K
Clinical Trial Data Disc Medicine, Inc. IRON

Disc Medicine Clinical Trial Data

Disc Medicine announced positive topline results from its pivotal Phase 3 APOLLO trial of bitopertin in patients with erythropoietic protoporphyria (EPP). The trial met all primary and secondary endpoints, including a 41.4% reduction in whole-blood PPIX and a significant increase in pain-free light tolerance, with an NDA resubmission planned by the end of 2026.

Term
6 months

“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”

John Quisel, J.D., Ph.D., President and Chief Executive Officer

“These results are compelling evidence of the clinical benefit of a mechanism aimed at reducing the production of PPIX, the fundamental cause of disease. It has been an incredible journey from establishing the original hypothesis of targeting heme synthesis in cellular models to seeing that biology translate into the clear and meaningful clinical effects from APOLLO.”

Will Savage, M.D., Ph.D., Chief Medical Officer
7:05 AM ET 8-K
Clinical Trial Data EyePoint, Inc. EYPT

EyePoint Clinical Trial Data

EyePoint announced topline results from LUCIA, its second pivotal Phase 3 clinical trial of DURAVYU for wet age-related macular degeneration (wet AMD). The trial failed to meet its primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity (BCVA) compared to the aflibercept control, although it did meet secondary endpoints related to treatment burden reduction and safety.

6:31 AM ET 8-K
M&A Deal Barnwell Industries Inc BRN

Barnwell Industries M&A Deal with local Canadian corporation

Barnwell Industries provided a status update and Q&A regarding its previously announced agreement to sell its Canadian oil and natural gas business for C$9 million. The consideration includes C$4 million in cash and a 5% gross overriding royalty valued at C$5 million, which the buyer has an option to repurchase for C$5 million in the future.

Counterparty
local Canadian corporation
6:13 AM ET 8-K
Contract Win Transocean Ltd. RIG

Transocean Wins $550M Contract from undisclosed operator

Transocean Ltd. secured two ultra-deepwater drillship contracts in the U.S. Gulf of Mexico totaling approximately $550 million in firm backlog. The Deepwater Proteus was awarded a 700-day, ten-well campaign valued at $325 million, while the Deepwater Conqueror received a 450-day, five-well award valued at $225 million.

Value
$550M
Counterparty
undisclosed operator
Term
700 days and 450 days
6:11 AM ET 8-K/A
M&A Deal reAlpha Tech Corp. AIRE

reAlpha Tech M&A Deal with InstaMortgage Inc.

reAlpha Tech Corp. filed an amendment to its previous 8-K to provide updated audited financial statements for InstaMortgage Inc., which it acquired on August 19, 2026. This filing specifically corrects an inadvertent reference to government auditing standards in the auditor's report and provides the necessary financial exhibits required for the completed merger.

Counterparty
InstaMortgage Inc.
6:04 AM ET 8-K
M&A Deal OpenWorld, Inc. OPNW

OpenWorld M&A Deal with Blocksight Holdings Co.

OpenWorld, Inc. has entered into a definitive merger agreement to acquire Blocksight Holdings Co., an AI agent developer for real-world asset tokenization. The acquisition will be settled via the issuance of 641,924 shares of OpenWorld common stock, representing 4% of the company's post-merger fully diluted capitalization. Blocksight's AI agents will be integrated into the OpenWorld Enterprise platform to automate deal structuring and reporting for over $1.1 billion in recently announced tokenized financing programs.

Counterparty
Blocksight Holdings Co.
6:01 AM ET 8-K
M&A Deal Archimedes Tech SPAC Partners II Co. ATII

Archimedes Tech SPAC Partners II M&A Deal with Forge Nano, Inc.

Archimedes Tech SPAC Partners II Co. (ATII) announced that its shareholders approved the previously announced business combination with Forge Nano, Inc. at an extraordinary general meeting. The deal is expected to close in the coming days, after which the combined company will operate as Forge Nano Holdings, Inc. and trade on Nasdaq under the ticker symbol 'NANO'.

Counterparty
Forge Nano, Inc.
5:30 PM ET 8-K/A
M&A Deal Powerus Corp PUSA

Powerus M&A Deal with Autonomous Power Corporation

Powerus Corporation filed an amendment to its previous 8-K to provide required financial statements and pro forma information following its completed acquisition of Autonomous Power Corporation (Legacy Powerus). The acquisition was completed on October 1, 2026, pursuant to a merger agreement originally dated March 8, 2026.

Counterparty
Autonomous Power Corporation
5:15 PM ET 8-K
Licensing Deal DataMeds AI, Inc. MEDS

DataMeds AI Licensing Deal with REBOOT Health AI, Inc. Worth $2M

DataMeds AI, Inc. entered into an exclusive intellectual property license agreement with REBOOT Health AI to use its AI platform for DataMeds' GLP-1 weight management business. As consideration, DataMeds will issue 666,667 shares of common stock with a guaranteed minimum value of $2 million after 180 days, plus a revenue-sharing arrangement. The company also disclosed it remains below Nasdaq's minimum stockholders' equity requirement for continued listing.

Value
$2M
Counterparty
REBOOT Health AI, Inc.
Term
perpetuity
5:14 PM ET 8-K
M&A Deal Mobix Labs, Inc MOBX

Mobix Labs M&A Deal with Special Project Delivery, Inc.

Mobix Labs provided a status update on its pending acquisition of Special Project Delivery (SPD) and announced that SPD has entered into a definitive agreement to acquire Winner Water Services. The transactions are part of Mobix Labs' 'National Security Matters' initiative to expand into the rare earths and critical minerals market.

Counterparty
Special Project Delivery, Inc.
5:09 PM ET 8-K
Nasdaq/NYSE Compliance Notice Apollo Commercial Real Estate Finance, Inc. ARI

Apollo Commercial Real Estate Finance Nasdaq/NYSE Compliance Notice

Apollo Commercial Real Estate Finance, Inc. announced it will voluntarily delist its common stock from the NYSE on or about October 27, 2026, with the last day of trading expected to be November 6, 2026. This action is part of the company's Plan of Complete Liquidation and Dissolution, which involves transferring remaining assets to a liquidating trust and deregistering with the SEC. Following the transfer, stockholders will receive non-transferable beneficial interests in the trust on a one-for-one basis.

Counterparty
New York Stock Exchange
5:04 PM ET 8-K
Capital Raise Iambic Therapeutics, Inc. IAM

Iambic Therapeutics Capital Raise

Iambic Therapeutics, Inc. filed an amended and restated certificate of incorporation and adopted restated bylaws in connection with the completion of its initial public offering (IPO). The filing formalizes the company's corporate governance structure as it transitions to a publicly traded entity on the Nasdaq Stock Market.

5:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice Bridgeline Digital, Inc. BLIN

Bridgeline Digital Nasdaq/NYSE Compliance Notice

Bridgeline Digital received a deficiency notice from Nasdaq on October 14, 2026, because its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, until April 12, 2027, to regain compliance by maintaining a $1.00 bid price for at least 10 consecutive business days.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days
5:01 PM ET 8-K
Nasdaq/NYSE Compliance Notice Canopy Growth Corp CGC

Canopy Growth Nasdaq/NYSE Compliance Notice

Canopy Growth Corporation received a deficiency notice from Nasdaq on October 14, 2026, because its common shares closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 12, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Canopy Growth is currently seeking shareholder approval for a potential reverse stock split at its upcoming annual meeting to address the deficiency.

Counterparty
Nasdaq
Term
180 days
5:00 PM ET 8-K
Capital Raise IonQ, Inc. IONQ

IonQ Capital Raise of $2B

IonQ, Inc. entered into an underwriting agreement for a public offering of 20.5 million shares of common stock and 29.5 million pre-funded warrants, each paired with two Series C warrants. The combined offering price is $40.00 per share/pre-funded warrant, resulting in gross proceeds of approximately $2 billion. The Series C warrants have an exercise price of $69.46 per share and a seven-year term.

Value
$2B
Counterparty
J.P. Morgan Securities LLC
4:52 PM ET 8-K
Divestiture Eaton Corp plc ETN

Eaton Corp Divestiture

Eaton Corporation plc announced its intention to pursue a tax-free spin-off of its Mobility business, which includes its legacy Vehicle and eMobility operating segments, into an independent, publicly traded company. The company also highlighted recent M&A activity, including the completed acquisition of Ultra PCS Limited and the pending acquisition of Boyd Thermal to expand its data center cooling portfolio.

4:47 PM ET 8-K
Capital Raise Alector, Inc. ALEC

Alector Capital Raise of $75M

Alector, Inc. entered into an underwriting agreement to sell 36,600,000 shares of common stock in a public offering at $2.05 per share. The company expects to receive gross proceeds of approximately $75 million to fund research, development, and general corporate purposes. The offering includes participation from institutional investors including TCGX and BVF Partners.

Value
$75M
Counterparty
Morgan Stanley & Co. LLC
4:31 PM ET 8-K
Nasdaq/NYSE Compliance Notice Lucid Diagnostics Inc. LUCD

Lucid Diagnostics Nasdaq/NYSE Compliance Notice

Lucid Diagnostics Inc. received a deficiency notice from Nasdaq on October 12, 2026, because its common stock closing bid price fell below the $1.00 minimum requirement for 30 consecutive business days. The company has 180 calendar days, until April 12, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days.

Counterparty
Nasdaq
Term
180 days
4:30 PM ET 8-K
Nasdaq/NYSE Compliance Notice Health In Tech, Inc. HIT

Health In Tech Nasdaq/NYSE Compliance Notice

Health In Tech received two deficiency notices from Nasdaq regarding its failure to maintain a majority of independent directors on its board and for its stock price falling below the $1.00 minimum bid requirement for 30 consecutive days. The company has until April 12, 2027, to regain compliance with the bid price rule and until its next annual meeting to resolve the board independence issue. Management expects to regain compliance following the election of a new independent director at the annual meeting scheduled for November 10, 2026.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days
4:15 PM ET 8-K
Capital Raise Amaze Holdings, Inc. AMZE

Amaze Holdings Capital Raise

Amaze Holdings, Inc. entered into a securities purchase agreement with C/M Capital Master Fund, LP for a $100 million committed equity facility. The company has the right, but not the obligation, to sell shares of its common stock to the fund over a 36-month term at a discount to market prices. This facility provides the company with a flexible source of capital to fund its operations based on market conditions.

Counterparty
C/M Capital Master Fund, LP
Term
36 months
4:11 PM ET 8-K
Nasdaq/NYSE Compliance Notice eHealth, Inc. EHTH

eHealth Nasdaq/NYSE Compliance Notice

eHealth, Inc. received a deficiency notice from Nasdaq on October 14, 2026, because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 calendar days, until April 12, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Management is considering options to regain compliance, including a potential reverse stock split or transferring to the Nasdaq Capital Market.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days
4:10 PM ET 8-K
Nasdaq/NYSE Compliance Notice Callan Jmb Inc. CJMB

Callan Jmb Nasdaq/NYSE Compliance Notice

Callan JMB Inc. received a Staff Determination letter from Nasdaq on October 12, 2026, notifying the company of its failure to regain compliance with the $2.5 million minimum stockholders' equity requirement. The company has requested a hearing before a Nasdaq Hearings Panel to appeal the delisting determination, which stays the suspension of its common stock pending the Panel's decision.

Counterparty
The Nasdaq Stock Market LLC
4:08 PM ET 8-K/A
M&A Deal Deluxe Corp DLX

Deluxe M&A Deal with Celero Commerce

Deluxe Corporation filed an amendment to its previous 8-K to provide required audited and pro forma financial statements following its completed acquisition of Celero Commerce. The filing includes Celero's consolidated financial statements for the years 2024 and 2025, as well as interim 2026 data, to satisfy SEC reporting requirements for material acquisitions.

Counterparty
Celero Commerce
4:08 PM ET 8-K
M&A Deal Aibotics, Inc. AIBT

Aibotics M&A Deal with PlayJamaica Limited

Aibotics, Inc. entered into a definitive agreement to acquire the robotics, drone services, AI, and mapping assets of PlayJamaica Limited for an initial consideration of $225,000 in Series B Preferred Stock. The deal includes an earn-out provision where PlayJamaica can receive up to an additional $3 million in preferred stock based on achieving $5 million in cumulative revenue over four years. Aibotics also committed to deploying $1 million in capital into the newly formed NovaCore Labs subsidiary over the next 12 months.

Counterparty
PlayJamaica Limited
4:06 PM ET 8-K
Nasdaq/NYSE Compliance Notice Aether Holdings, Inc. ATHR

Aether Holdings Nasdaq/NYSE Compliance Notice

Aether Holdings received a deficiency notice from Nasdaq for failing to hold an annual meeting of shareholders within 12 months of its fiscal year end. The company has until November 27, 2026, to submit a compliance plan and may be granted until March 29, 2027, to regain compliance.

Counterparty
Nasdaq
4:06 PM ET 8-K/A
M&A Deal StageWise Strategies Corp. TEGO

Teg Overseas M&A Deal with Teg SPV LLC

TEG Overseas, Inc. (formerly StageWise Strategies Corp.) completed the acquisition of participatory interests in TEG SPV LLC following official registration in the Republic of Uzbekistan. The closing triggered a significant board overhaul, with five new directors appointed and the resignation of three previous members, alongside a change in the company's fiscal year end to December 31.

Counterparty
TEG SPV LLC
4:05 PM ET 8-K
Nasdaq/NYSE Compliance Notice Site Centers Corp. SITC

Site Centers Nasdaq/NYSE Compliance Notice

SITE Centers Corp. has provided written notice to the NYSE of its intention to voluntarily delist its common shares. The company expects the delisting to become effective prior to the commencement of trading on December 4, 2026, following the sale of its interests in the Dividend Trust Portfolio joint venture.

Counterparty
New York Stock Exchange
4:05 PM ET 8-K
Capital Raise Oaktree Gardens OLP, LLC

Oaktree Gardens OLP Capital Raise of $25.6M

Oaktree Gardens OLP, LLC issued 1,281,281.28 common units at a price of $19.98 per unit, raising $25.6 million in gross proceeds. The issuance was conducted via a capital call on October 14, 2026, in reliance on a Section 4(a)(2) private placement exemption.

Value
$25.6M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.